WO2023031855 - SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS
National phase entry:
Publication Number
WO/2023/031855
Publication Date
09.03.2023
International Application No.
PCT/IB2022/058233
International Filing Date
01.09.2022
Title **
[English]
SUBSTITUTION OF NUCLEOTIDE BASES IN SELF-AMPLIFYING MESSENGER RIBONUCLEIC ACIDS
[French]
SUBSTITUTION DE BASES NUCLÉOTIDIQUES DANS DES ACIDES RIBONUCLÉIQUES MESSAGERS AUTO-AMPLIFICATEURS
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors
KONG, Qiongman
MARUGGI, Giulietta
ROY, Varnika
YU, Dong
ZHANG, Meng
Priority Data
63/240,502
03.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7311 | |
| EPO | Filing, Examination, Granting | 30212 | |
| Japan | Filing, Examination, Granting | 2702 | |
| South Korea | Filing, Examination, Granting | 2990 | |
| USA | Filing, Examination, Granting | 12940 |
Total:
56,155
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are RNA that: are collectively self-amplifying in an intracellular environment, comprise N1-methylpseudouridines and uridines, and have a mole percentage or mole proportion of the N1-methylpseudouridines to the total of the uridines and the N1-methylpseudouridines or a mole ratio of the N1-methylpseudouridines to the uridines.[French]
L'invention concerne des ARN qui sont collectivement auto-amplificateurs dans un environnement intracellulaire, comprennent des N1-méthylpseudouridines et des uridines, et ont un pourcentage molaire ou une proportion molaire des N1-méthylpseudouridines par rapport au total des uridines et des N1-méthylpseudouridines ou un rapport molaire des N1-méthylpseudouridines par rapport aux uridines.